Gyre Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	117.05	116.59	105.76	113.45	102.29	7.34
Revenue Growth (YoY)	16.30%	10.24%	-6.78%	10.91%	1293.98%	-82.48%
Cost of Revenue	5.75	5.42	3.88	4.64	4.79	7.38
Gross Profit	111.3	111.17	101.87	108.81	97.5	-0.04
Selling, General & Admin	91.54	85.98	73.62	75.82	71.61	18.96
Research & Development	17.34	13.7	12.02	13.78	16.69	68.89
Other Operating Expenses	2.56	0	0.07	86.44	-	-
Total Operating Expenses	111.44	99.69	85.71	176.04	88.29	87.85
Operating Income	-0.14	11.49	16.16	-67.23	9.2	-87.89
Interest Income	0.51	1.75	1.55	1.04	1.58	-
Other Non-Operating Income (Expense)	-1.04	1.2	5.51	-10.78	-1.37	-0.04
Total Non-Operating Income (Expense)	-1.04	2.95	7.06	-9.74	0.21	-0.04
Pretax Income	0.56	14.44	23.22	-76.97	9.41	-87.93
Provision for Income Taxes	4.28	4.56	5.32	8.52	5.1	-
Net Income	-6.36	5.03	12.09	-92.93	2.3	-87.93
Minority Interest in Earnings	2.65	4.85	5.81	7.45	2.01	-
Net Income to Common	-6.36	5.03	12.09	-92.93	2.3	-87.93
Net Income Growth	-	-58.40%	-	-	-	-
Shares Outstanding (Basic)	91	89	85	66	64	61
Shares Outstanding (Diluted)	97	103	102	66	76	67
Shares Change (YoY)	-0.92%	0.87%	55.39%	-13.02%	13.45%	5117.44%
EPS (Basic)	-0.08	0.06	0.14	-1.41	0.04	0.26
EPS (Diluted)	-0.09	0.02	0.05	-1.41	0.03	0.24
EPS Growth	-	-60.00%	-	-	-87.50%	-
Shares Outstanding	91.34	91.31	86.31	76.6	63.59	2.09
Free Cash Flow	3.07	-0.18	-5.96	17.38	5.69	-84.59
Free Cash Flow Growth	-	-	-	205.25%	-	-
Free Cash Flow Per Share	0.03	-0.00	-0.06	0.26	0.08	-1.27
Gross Margin	95.09%	95.35%	96.33%	95.91%	95.31%	-0.57%
Operating Margin	-0.12%	9.85%	15.28%	-59.26%	9.00%	-1197.79%
Profit Margin	-3.17%	8.47%	16.92%	-75.35%	4.22%	-1198.32%
FCF Margin	2.63%	-0.15%	-5.63%	15.32%	5.56%	-1152.82%
EBITDA	2.48	13.97	17.71	-66.16	10.29	-87.6
EBITDA Margin	2.12%	11.98%	16.75%	-58.31%	10.06%	-1193.84%
EBIT	-0.14	11.49	16.16	-67.23	9.2	-87.89
EBIT Margin	-0.12%	9.85%	15.28%	-59.26%	9.00%	-1197.79%
Effective Tax Rate	758.16%	31.56%	22.91%	-11.06%	54.16%	0.00%

Updated May 8, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q